Literature DB >> 16157901

LRRK2 gene in Parkinson disease: mutation analysis and case control association study.

C Paisán-Ruíz1, A E Lang, T Kawarai, C Sato, S Salehi-Rad, G K Fisman, T Al-Khairallah, P St George-Hyslop, A Singleton, E Rogaeva.   

Abstract

BACKGROUND: In addition to the four well-confirmed genes linked to early-onset Parkinson disease (PD) (SNCA, PARKIN, DJ-1, and PINK1), mutations in the leucine-rich repeat kinase 2 gene (LRRK2) have recently been identified in families with autosomal dominant late-onset PD.
OBJECTIVE: To perform mutation analysis of LRRK2 in probands of families showing dominant inheritance of PD and to conduct a case control association study to test the hypothesis that common coding variations might be associated with increased susceptibility to PD.
METHODS: All 51 LRRK2 coding exons were sequenced in 23 probands and the mutation frequencies were evaluated in 180 neurologically normal control subjects. For the association study the authors genotyped four coding LRRK2 polymorphisms in 250 normal control subjects and 121 patients with PD (predominantly white patients of Canadian origin), 84% of whom had age at onset before 50 years and 42% had a positive family history.
RESULTS: The authors identified three probands with heterozygous LRRK2 mutations: two of them have the known G2019S substitution and one proband has a novel I1371V substitution. Mutation analysis of a large family demonstrated complete segregation of the G2019S with PD. However, there was no association between PD and any of the four polymorphisms at the allelic or genotypic levels (p > 0.17). Furthermore, the authors did not detect a modifying effect for any genotype or of APOE genotypes upon the age at onset in the PD group (p > 0.20).
CONCLUSIONS: The results support the prior suggestion that LRRK2 mutations cause PD. The disease in the families reported here presents a phenotype indistinguishable from typical PD. All three families demonstrate a very variable age at onset that is not explained by APOE genotypes. The common coding variations in the LRRK2 gene neither constitute strong PD risk factors nor modify the age at onset; however, the possibility of a modest risk effect remains to be assessed in large datasets.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16157901     DOI: 10.1212/01.wnl.0000167552.79769.b3

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  42 in total

1.  A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan.

Authors:  Alessio Di Fonzo; Yah-Huei Wu-Chou; Chin-Song Lu; Marina van Doeselaar; Erik J Simons; Christan F Rohé; Hsiu-Chen Chang; Rou-Shayn Chen; Yi-Hsin Weng; Nicola Vanacore; Guido J Breedveld; Ben A Oostra; Vincenzo Bonifati
Journal:  Neurogenetics       Date:  2006-04-22       Impact factor: 2.660

Review 2.  Redefining Parkinson's disease research using induced pluripotent stem cells.

Authors:  Jiali Pu; Houbo Jiang; Baorong Zhang; Jian Feng
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

3.  Association between Parkinson's disease and G2019S and R1441C mutations of the LRRK2 gene.

Authors:  Xiao-Xia Li; Qin Liao; Huan Xia; Xin-Ling Yang
Journal:  Exp Ther Med       Date:  2015-07-27       Impact factor: 2.447

4.  The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence.

Authors:  E K Tan; Y Zhao; L Skipper; M G Tan; A Di Fonzo; L Sun; S Fook-Chong; S Tang; E Chua; Y Yuen; L Tan; R Pavanni; M C Wong; P Kolatkar; C S Lu; V Bonifati; J J Liu
Journal:  Hum Genet       Date:  2006-09-30       Impact factor: 4.132

5.  LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress.

Authors:  Ha Nam Nguyen; Blake Byers; Branden Cord; Aleksandr Shcheglovitov; James Byrne; Prachi Gujar; Kehkooi Kee; Birgitt Schüle; Ricardo E Dolmetsch; William Langston; Theo D Palmer; Renee Reijo Pera
Journal:  Cell Stem Cell       Date:  2011-03-04       Impact factor: 24.633

Review 6.  Advances in the discovery of genetic risk factors for complex forms of neurodegenerative disorders: contemporary approaches, success, challenges and prospects.

Authors:  Sumeet Kumar; Navneesh Yadav; Sanjay Pandey; B K Thelma
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

7.  The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition.

Authors:  Jason P Covy; Benoit I Giasson
Journal:  J Neurochem       Date:  2010-08-19       Impact factor: 5.372

8.  Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease.

Authors:  Roy N Alcalay; Helen Mejia-Santana; Ming Xin Tang; Llency Rosado; Miguel Verbitsky; Sergey Kisselev; Barbara M Ross; Elan D Louis; Cynthia L Comella; Amy Colcher; Danna Jennings; Martha A Nance; Susan Bressman; William K Scott; Caroline Tanner; Susan F Mickel; Howard F Andrews; Cheryl H Waters; Stanley Fahn; Lucien J Cote; Steven J Frucht; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald Pfeiffer; Laura Marsh; Bradley Hiner; Andrew Siderowf; Elise Caccappolo; Ruth Ottman; Lorraine N Clark; Karen S Marder
Journal:  Arch Neurol       Date:  2009-12

9.  Parkin Exon Rearrangements and Sequence Variants in LRRK2 Mutations Carriers: Analysis on a Possible Modifier Effect on LRRK2 Penetrance.

Authors:  Paolo Solla; Antonino Cannas; Gianluca Floris; Maria Rita Murru; Daniela Corongiu; Stefania Tranquilli; Stefania Cuccu; Marcella Rolesu; Francesco Marrosu; Maria Giovanna Marrosu
Journal:  Parkinsons Dis       Date:  2010-08-19

Review 10.  Association between the ubiquitin carboxyl-terminal esterase L1 gene (UCHL1) S18Y variant and Parkinson's Disease: a HuGE review and meta-analysis.

Authors:  Margaret Ragland; Carolyn Hutter; Cyrus Zabetian; Karen Edwards
Journal:  Am J Epidemiol       Date:  2009-10-28       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.